Dogwood Therapeutics financials
$1.35−0.74%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$28.0M | -$12.2M |
| Net income | -$35.5M | -$12.9M |
| Net margin | — | — |
| Diluted EPS | $-7.13 | $-12.52 |
| EBITDA | -$28.0M | -$12.2M |
| Operating cash flow | -$15.6M | -$8.8M |
| Free cash flow | -$15.6M | -$8.8M |
| Diluted shares | 5.0M | 1.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $6.5M | $14.8M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 |
| Total assets | $90.2M | $94.3M |
| Total liabilities | $15.3M | $30.0M |
| Shareholders' equity | $74.9M | -$10.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology